Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sublingual Sufentanil for Moderate to Severe Monotraumatic Pain in the ED
NCT06917651Phase 3Recruiting
- Sponsor
- Centre Hospitalier Universitaire de Clermont-Ferrand
- Start
- Apr 2025
- Primary completion
- Apr 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised trial of SurBred in pain (2 arms), sponsored by Centre Hospitalier Universitaire de Clermont-Ferrand. Primary endpoint: Pain Score on the Numerical Rating Scale at 1 hour. Started Apr 2025; status: recruiting.
02
Drugs
SurBred
03
Conditions
pain
Beyond the preview
Go deeper on NCT06917651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06917651.